Marko Krošelj

Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients

Mark Konijnenberg, Petra Kolenc Peitl, Piotr Garnuszek et al. · European Journal of Pharmaceutical Sciences · 2016 · 50 citations · Full text

Medicine, Nuclear Medicine, Pharmacokinetics +17

From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial

Dariusz Pawlak, Christine Rangger, Petra Kolenc Peitl et al. · European Journal of Pharmaceutical Sciences · 2016 · 35 citations · Full text

Medicine, Nuclear Medicine, Pharmacology +17

Stereochemistry of Amino Acid Spacers Determines the Pharmacokinetics of¹¹¹In–DOTA–Minigastrin Analogues for Targeting the CCK2/Gastrin Receptor

Petra Kolenc Peitl, Maria‐Luisa Tamma, Marko Krošelj et al. · Bioconjugate Chemistry · 2015 · 26 citations

Medicine, Pharmacokinetics, Pharmacology +15

On-cartridge preparation and evaluation of 68Ga-, 89Zr- and 64Cu-precursors for cell radiolabelling

Aljaž Sočan, Miloš Petřík, Petra Kolenc Peitl et al. · Nuclear Medicine and Biology · 2019 · 21 citations

Natural Sciences, Cell Biology, Chemistry +13

Radiolabelled CCK₂R Antagonists Containing PEG Linkers: Design, Synthesis and Evaluation

Doroteja Novak, Tihomir Tomašič, Marko Krošelj et al. · ChemMedChem · 2020 · 13 citations

Pharmacy, Medicinal Chemistry, Pharmacology +11